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Chronic Fatigue Syndrome (CFS) is a multisystem illness, which may be associated with
imbalances in gut microbiota. This study builds on recent evidence that sleep may be
inﬂuenced by gut microbiota, by assessing whether changes to microbiota in a clinical
population known to have both poor sleep and high rates of colonization with gram-
positive faecal Streptococcus, can improve sleep. Twenty-one CFS participants completed a
22- day open label trial. Faecal microbiota analysis was performed at baseline and at the
end of the trial. Participants were administered erythromycin 400 mg b.d. for 6 days.
Actigraphy and questionnaires were used to monitor sleep, symptoms and mood. Changes
in patients who showed a clinically signiﬁcant change in faecal Streptococcus after
treatment (responders; deﬁned as post-therapy distributiono6%) were compared to
participants who did not respond to treatment. In the seven responders, there was a
signiﬁcant increase in actigraphic total sleep time (p¼0.028) from baseline to follow up,
compared with non-responders. Improved vigour scores were associated with a lower
Streptococcus count (ρ¼0.90, p¼0.037). For both the responders and the whole group,
poorer mood was associated with higher Lactobacillus. Short term antibiotic treatment
appears to be insufﬁcient to effect sustainable changes in the gut ecosystem in most CFS
participants. Some improvement in objective sleep parameters and mood were found inep. Production and Hosting by Elsevier B.V. This is an open access article under the CC BY-
licenses/by-nc-nd/4.0/).
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S l e e p S c i e n c e 8 ( 2 0 1 5 ) 1 2 4 – 1 3 3 125participants with reduced levels of gram-positive gut microbiota after antibiotic treatment,
which is encouraging. Further study of possible links between gut microorganisms and
sleep and mood disturbances is warranted.
& 2015 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic Fatigue Syndrome (CFS) is a multisystem illness,
associated with disabling fatigue, cognitive dysfunction and
sleeping disturbances. In 1992 the WHO approved the term
“Chronic Fatigue Syndrome” and recognized this disorder as a
neurological disease (WHO ICD-10 G93.3). CFS is characterized
by persistent and relapsing fatigue, post exertional malaise
(both physical and mental), cognitive and mood changes, and
gastrointestinal disturbance and food intolerances. In addi-
tion, sleep disturbances and unrefreshing sleep are com-
monly reported by these patients [1]. While there are now
internationally recognized criteria for diagnosing this disor-
der, the cause (or causes) remains elusive [2].
Recent developments support the model of CFS as a
multisystem illness with symptoms that are due to gastro-
intestinal and neurotoxic features, on a background of
immunological dysfunction. Importantly, discoveries in
recent years reinforce the idea that CFS is associated with
imbalances in intestinal microbiota (dysbiosis) [3]. Sheedy
and colleagues have reported higher levels of gram-positive
bacteria, particularly Enterococcus and Streptococcus spp., in
CFS patients compared to controls, in whom the levels were
5.0106 and 8.9104 cfu/L respectively [4]. Streptococcus spp.
are gram-positive, facultative anaerobic organisms and are
classiﬁed as homofermenative, producing predominantly
lactic acid from glucose catabolism and generally regarded
as potent D- and L-lactic acid producers [4]. Increased propor-
tions of lactic acid in the intestine may result in a change in
the distribution of both the facultative anaerobic and anae-
robic microbiome (the collective genomes of the microorgan-
isms in the gut), thus giving rise to a vicious cycle. Increased
distribution of lactic acid bacteria (Streptococcus, Enterococcus
sp.) may lower the colonic pH [5], modify faecal microbiota
metabolism, and alter intestinal epithelial barrier function,
increasing passive intestinal permeability [6]. Accumulation
of D-lactate in the intestine can also push absorption into the
blood. Circulating D-lactate can cross the blood-brain barrier,
resulting in neurological symptoms, including delirium,
ataxia and slurred speech. This has been termed the D-
lactate hypothesis [7]. D-lactic acid accumulation is typically
found in patients with short bowel syndrome, and has been
linked to cognitive and mood changes in animals [8,9] and
humans [4].
We have previously proposed a link between intestinal
colonization of gram-positive bacteria and expression of CFS
symptoms in a subgroup of patients [10]. Recent evidence
supports a decade-old contention that intestinal dysbiosis
can profoundly affect multiple aspects of sleep, mood and
cognitive function [11]. The gastrointestinal system is animportant organ for the equilibrium of health, and has been
found to have a bidirectional relationship with the central
nervous system (CNS) [12]; referred to as the “gut-brain axis”.
Intestinal bacteria can communicate with the CNS through
vagal sensory nerve ﬁbres and the peripheral immune sys-
tem. In patients with functional bowel disease (e.g. some
CFS), increased colonization of faecal gram-positive bacteria
is associated with neurologic dysfunctions (inability to con-
centrate, excessive irritability, confusion, impaired motor
coordination [13]). Further research into the bidirectional
relationship between intestinal dysbiosis and symptom
expression including sleep problems [1] in patients with CFS
is needed.
If altered intestinal microbiota contributes to the patho-
genesis of CFS, then therapeutics that rebalance or modify
intestinal microbiota may have the potential to reduce
symptoms [14]. Only two studies to date have examined the
effect of probiotic treatment on mood symptoms in indivi-
duals with CFS [15,16]. In an uncontrolled study by Sullivan
and colleagues, 15 CFS patients completed four weeks of
probiotic therapy (Lactobacillus acidophilus and Biﬁdobacterium
lactis). While no change in intestinal microbiota was
observed, six of 15 patients reported improvements in fatigue
and mood following treatment, with an overall improvement
in neurocognitive function. These ﬁndings were partially
replicated by Rao and colleagues [15], who reported signiﬁ-
cant decreases in anxiety symptoms in 39 CFS patients after
ingesting Lactobacillus casei strain Shirtota for two months
compared to placebo.
While these studies lend support to the notion that
alterations in gut microbiota can change subjective symptom
expression, as outlined above, it is likely that many CFS
patients experience intestinal dysbiosis, warranting the use
of antibiotic treatment to the return of a balanced microbial
ecology. Only one pilot study has reported on symptoms in
four CFS patients after three months of antibiotic treatment
for Coxiella burnetti infection [17]. After treatment, patients
were reported to be negative for infection, but their CFS
symptoms remained unchanged. There has been no systema-
tic study to explore real world improvements in sleep quality
and daytime symptoms, following antibiotic treatment for
intestinal dysbiosis in people who suffer CFS, and this area
requires further research.
This study aims to determine if participants with CFS who,
at baseline, are predominantly colonized with gram-positive
faecal Streptococcus (determined by stool analysis and sugges-
tive of abnormal gut functioning) will demonstrate signiﬁcant
improvements in sleep (measured by objective actigraphy
and subjective self-reporting diary), fatigue, mood and self-
reported CFS symptoms after a six-day antibiotic treatment
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will be considered separately for those who were found to
(i) respond to the antibiotic treatment, by a reduction in the
Streptococcus distribution, compared to those who did not
respond with such reduced distribution, and (ii) the whole
sample.2. Methods
2.1. Participants
The ﬁnal sample who completed the trial consisted of 22 CFS
patients (5 males), aged between 23 and 66 (mean age
41.8712.2). The inclusion criteria at entry to the study were:
meet CFS criteria according to the Canadian consensus
document [18]; be aged over 18 years; not currently on
antibiotics and not been on antibiotics for four weeks prior
to Baseline phase; not been on any non-prescription probio-
tics for at least two weeks prior to Baseline; not currently
taking any prescription hypnotics (this does not include
melatonin); no evidence of a sleep disorder (apart from
insomnia); have an Epworth Sleepiness Scale score o15;
agree to maintain their current intake of any over-the-
counter supplements and/or permitted prescription tablets
over the entire 22 day period (if relevant). If any changes were
made to their current medication, they were asked to notify
the researchers at the time of the change. Those who met the
initial inclusion criteria were then asked to complete a
Bioscreen FMA test to conﬁrm they met the threshold
gram-positive count (Streptococcus43105 cfu/g). Details of
participant numbers meeting different screening criteria are
presented in the Results. This study was approved by the
institution's Human Research Ethics Committee, and written
informed consent was obtained from all participants. The
trial was registered with the Australian and New Zealand
Clinical Trial Registry (ACTRN12615000457549).
2.2. Measures
Epworth Sleepiness Scale is a widely used 8-item scale for
determining whether a person has excessive daytime sleepi-
ness [19]. A score 415 indicates signiﬁcant sleepiness difﬁ-
culties and would be inconsistent with a CFS diagnosis
without further investigation by a sleep specialist, and there-
fore this was used as the cut-off exclusion criteria.
The Multivariable Apnea Prediction Index is a 13 item vali-
dated measure uses an individual's body mass index, age,
gender and scores on three questions related to sleep apnea
(snorting and gasping, loud snoring, and breathing stops) to
calculate the probability of sleep apnea [20]. Scores40.5 were
used as the cut-off for study exclusion.
Day & Sleep Diary A day and sleep diary was completed
each morning (sleep) and night (day) for 22 days, and the data
was used to assist in the interpretation of the wrist actigra-
phy output (e.g. time of lights out). The day diary asked
participants, prior to bed, to assess various physical symp-
toms and selected mood and cognitive variables during the
day, including 11 items from the Chalder Fatigue Scale [21], a
pain rating scale (1¼poor, 10¼excellent), and experience ofCFS symptoms (1¼ better than usual, 4¼much worse than
usual). The sleep diary asked participants to note their time
of getting into bed, lights out, number of awakenings during
the night, and the time they woke and got out of bed, each
morning of the study. In addition, it provided subjective
assessments of sleep quality, on a 10 point scale (1¼poor,
10¼excellent).
The Proﬁle of Mood States Short Form (POMS; [22]) consists of
37 adjectives that are rated by subjects on a 5-point scale,
over a 7 day time period. Six factors have been derived from
this: tension-anxiety, depression-dejection, anger-hostility,
fatigue-inertia, vigor-activity, and confusion-bewilderment.
The Symptom Severity and Severity Hierarchy Proﬁle consists
of a list of 21 common symptoms of CFS, that are rated on a
four point scale (0¼absent – 3¼severe), and rank in order of
severity [23].
An Actiwatch monitor (Respironics Actiwear 2) was used
to objectively assess sleep via actigraphy, which has been
used previously in this population [24]. The wrist Actiwatch
was worn on the non-dominant wrist of participants for the
duration of the study, and measured 24-h activity levels in
60 second epochs. An algorithm yields approximate values
for sleep efﬁciency, sleep onset latency (SOL), wake after
sleep onset (WASO), rest time (time in bed), number of wake
bouts, total sleep time (TST) and sleep fragmentation index
(SFI). Daytime activity and light exposure levels were also
recorded (but not analyzed in this study). In order to remove
any wash-in or wash-out effect of the treatment, the middle
four days of actigraphy for the baseline and treatment
periods was used in the analysis. The post treatment period
was further divided into two four-day periods (post treatment
1 and post treatment 2).
2.3. Procedure
This study involved an open label trial over 22 days. Potential
participants were recruited from the CFS Discovery Centre
and cared for by one investigator (DL). They were provided
information about the study from the clinic staff. Interested
patients were asked to contact the researchers directly, who
then mailed sleep and health screening questionnaires to the
potential participants. Consent was obtained from partici-
pants who met the sleep and general health criteria. A faecal
microbiota analysis (FMA) test kit was sent to each partici-
pant for analysis. Four lactic acid producing organisms
(Streptococcus, Enterococcus, Lactobacillus and Biﬁdobacterium)
from each of the submitted faecal samples were investigated
by Bioscreen Pty Ltd. Participants were included in the study
if the FMA test showed increased colonization of Streptococcus
sp. (deﬁned as 43105 cfu/g of faecal sample). The preva-
lence of the remaining three lactic acid producing organisms,
Enterococcus, Lactobacillus and Biﬁdobacterium, were also
assessed. Faecal organisms were identiﬁed by MALDI-TOF
MS (Matrix Assisted Laser Desorption Ionization- Time of
Flight Mass Spectrometry). All participants included in the
study were treated with erythromycin 400 mg b.d, at Day 8 for
6 days. Each participant included in the study also received
an Actiwatch and completed a sleep diary each morning and
evening.
                       Study phase Screening Baseline Treatment Post treatment 
                                                 Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Acitgraphy & Sleep diary X X X X X X X X X X X X X X X X X X X X X X
Antibiotic X X X X X X
CFS symptoms questionnaire X X
Chalder Fatigue Scale X X X
POMS X X X
Sleep quality rating X X
Bioscreen test           X  X o X
Fig. 1 – Study protocol.
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up protocol, across a total of 22 days (Fig. 1). This protocol was
chosen in order to collect sufﬁcient baseline and follow up
actigraphy of 7 days (including at least 5 week days), and to
allow for 6 days of antibiotic treatment.
The Actiwatch was worn continuously day and night and
sleep diaries completed in the morning and evening every
day throughout the study. During week 1, baseline measures
of sleep, symptoms and mood were recorded. On Day 8 parti-
cipants started their 6- day antibiotic treatment (erythromy-
cin). Six days of antibiotics was used as this is the standard
single course of treatment used in the clinic. A reminder note
was placed in the sleep diary, and participants were asked to
note any discrepancies in their treatment starting day or any
missed doses during the week. After the 6 days of treatment,
monitoring continued for a further 7 days to assess post-
intervention variables, including sleep. CFS symptoms were
assessed with the Symptoms Severity Proﬁle on Day 1 and
Day 21, and mood and fatigue was assessed at day 7, 15, and
22. A second FMA was performed at the end of the trial, either
on Day 22 or 23. A wash out period of 7 days between the ﬁnal
antibiotic dose and the follow-up FMA was chosen in order to
examine the immediate impact of the treatment once the
antibiotics were eliminated from the system.
2.4. Statistical analysis
Data analysis was conducted in two ways. Firstly, changes in
outcome measures in patients (termed here as “responders”)
who showed a signiﬁcant change in Streptococcus after anti-
biotic treatment (deﬁned as post-therapy percentage distri-
butiono6%) were compared to participants who did not show
such a drop in Streptococcus percentage distribution (non-
responders). Secondly, whole group analyses were conducted
for each outcome measure.
2.4.1. FMA
All data was checked for normality, and logarithmic transforma-
tions were conducted when this assumption was violated. The
FMA data, both before and after log transformation, did not meet
the normality assumption. Therefore, non-parametric Wilcoxon
tests were conducted to assess differences in FMA measures
from baseline to follow-up.
2.4.2. Actigraphy
Due to technical problems with the devices, actigraphy did
not record for four of the participants, leaving 18 participants
for the actigraphy analysis. Of these, 13 had complete data
across the 28 days, and the other ﬁve had partial data forsome of the protocol. All actigraphy measures were logarith-
mically transformed prior to analysis if they were not
normally distributed. There was two outliers in the sleep
efﬁciency and one for the total sleep time data (43 standard
deviations below the mean); these subjects were removed
from these analyses. For each actigraphic variable, analyses
were ﬁrst conducted within each group (responders and non-
responders) across baseline versus post-treatment week 2.
Difference scores between baseline and post-treatment 2 for
actigraphic variables were then compared between respon-
ders and non-responders. Due to small participant numbers
in the responders versus non-responder groups, non-
parametric Wilcoxon tests were used for both sets of ana-
lyses. Secondly, changes across the study (baseline; treat-
ment, post treatment 1, post treatment 2) were analyzed for
all the participants using repeated measures ANOVAs.
2.4.3. Subjective measures
Two participants in the responders group had only partial sleep
diary data, leaving six cases in the ﬁnal analysis of some of the
subjective measures. For the whole sample analyses, paired
samples t-test were conducted to assess differences in CFS
symptoms ratings, differences in mood (POMS total score and
subscales), Chalder Fatigue Scale and subjective sleep quality at
baseline (Day 7), after the antibiotic phase (post treatment 1, Day
14) and at the end of the trial (post treatment 2, Day 22).
Correlation analyses (Spearman's tests) were conducted
within the responders group and across the whole sample to
examine associations between all the subjective measures,
including the POMS subscales, and the three FMA results of
Streptococcus, Lactobacillus and Biﬁdobacterium counts and percen-
tage distribution at baseline and at the end of the trial (post
treatment 2).3. Results
3.1. Participant characteristics
A total of 70 patients were recruited in the study. Of these,
eight patients reported excessive daytime sleepiness or were
at risk of obstructive sleep apnea, one did not have any
signiﬁcant sleep issues, two were currently using sleeping
medication, three were currently on antibiotic or other treat-
ment, and one was not able to be contacted; these partici-
pants did not continue any further with the study. The
remaining 55 participants completed a FMA test, and of these
30 did not have streptococcal gut dysbiosis by the study
criteria, and were excluded. Twenty ﬁve participants had
Table 1 – Intestinal microbial viable counts and percen-
tage distribution of microorganisms from the FMA in CFS
patients at the start and end of the trial.
Baseline (N¼22) End of trial (N¼21)
Median (IQR) Median (IQR)
Streptococcus count 9.83þE06 (2.3þE06–
3.1þE07)
6.87Eþ06 (2.6Eþ05–
4.7Eþ07)
Enterococcus count 0.00 (0.00–2.3Eþ06) 0.00 (0.00–7.7Eþ04)
Lactobacillus count 7.05Eþ05 (0.00–
3.33Eþ08)
5.00Eþ05 (0.00–
7.0Eþ05)
Biﬁdobacterium
countn
5.5Eþ07 (5.0Eþ05–
1.7Eþ09)
5.00Eþ05 (0.00–
5.0Eþ07)
Streptococcus %n 72.36 (44.8–93.59) 39.54 (1.77–96.78)
Enterococcus % 0.00 (0.00–13.03) 0.00 (0.00–0.19)
Lactobacillus % 0.00 (0.00–0.22) 0.00 (0.00–0.01)
Biﬁdobacterium %n 0.24 (0.00–10.19) 0.00 (0.00–0.00)
n Wilcoxon test results po0.05.
Table 2 – Mean and standard deviations of actigraphy
variables for responders and non-responders, and p
levels for analyses of difference scores from baseline to
post treatment week 2.
Responders Non responders p#
N Mean SD N Mean SD
Baseline rest time
(min)
6 551.41 71.14 12 540.98 49.77
Post 2 rest time 4 566.31 46.04 9 494.20 71.58 4.10
Baseline sleep
efﬁciency (%)
6 68.05 27.65 11 77.91 11.19
Post treatment
2 sleep efﬁciency
(%)
4 78.42 9.26 9 81.70 9.62 .07
Baseline WASO
(min)
6 73.82 26.60 11 76.97 60.35
Post treatment
2 WASO (min)
4 90.94 32.91 9 60.99 44.92 4.10
Baseline TST (min) 6 397.14 159.86 11 427.16 63.24
Post treatment
2 TST (min)
4 441.88 21.15 9 412.73 58.96 .03
Baseline SOL (min) 6 42.07 63.57 11 20.75 18.88
Post treatment
2 SOL (min)
4 17.75 19.03 9 22.55 22.83 .08
Baseline number of
wake bouts
6 32.38 12.33 12 25.13 11.17
Post 2 number of
wake bouts
4 37.31 6.85 9 24.72 9.43 4.10
Baseline SFI 6 41.56 14.38 11 44.44 34.61
Post treatment
2 SFI
4 40.85 10.18 9 34.66 19.12 4.10
WASO¼wake after sleep onset; TST¼total sleep time; SOL¼sleep
onset latency; SFI ¼ sleep fragmentation index.
# Wilcoxeon test p levels, comparing the difference in responders
to the difference in non-responders (from baseline to post-
treatment week 2 for each group).
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faecal samples by the FMA test. Of these 25, two discontinued
prior to the trial commencing and one withdrew from the
study as the patient became unwell, leaving 22 participants
who completed the trial.
3.2. Faecal microbiota analysis (FMA)
Table 1 presents the data from the FMA at baseline and at the
end of the trial. The percentage distribution of Streptococcus in
relation to the total facultative anaerobic counts decreased
signiﬁcantly after antibiotic treatment (Wilcoxon¼2.17,
p¼0.030). While there was a reduction in Streptococcus counts
this did not reach statistical signiﬁcance. Thirteen of the
patients showed a reduction in Streptococcus counts after
treatment, whereas four patients showed an increase level
of Streptococcus and four patients had no change at the end
of the trial (as indicated by the exponent). Both the count
and percentage distribution of Biﬁdobacterium declined after
treatment (Wilcoxon¼2.76, p¼0.006, Wilcoxon¼2.92,
p¼0.004 respectively). Lactobacillus count also decreased after
treatment, although not signiﬁcantly (p¼0.060).
While 13 participants showed a reduction in Streptococcus
only 7 of these had a signiﬁcant change as deﬁned by a
percentage distribution post-therapy of less than 6% of
Streptococcus after antibiotic treatment (termed here as
“responders”). The remaining 14 tested at follow up did not
show such a drop in Streptococcus percentage distribution
(non-responders). In the 7 responders, both Streptococcus
viable count (1.34Eþ07 to 2.20Eþ06; p¼0.028) and percentage
distribution (45.5% to 3.57%; p¼0.018) signiﬁcantly decreased
after treatment. There was no signiﬁcant difference in age
(46.7712.6, 37.5710.5 years) between the responders and
non-responders (p¼0.70).
3.3. Actigraphy
Means and standard deviations of the four day averages for
the actigraphy measures for responders and non-responders
are shown in Table 2 for two time points. It can be seen that
statistical power was reduced by the low number ofresponders with actigraphy data, especially at the post-
treatment week 2 time point. These ﬁndings consistently
suggested more improvement in actigraphic sleep with treat-
ment in responders compared to non-responders from base-
line to post-treatment 2.
Total sleep time (TST) increased by 44 min from baseline
to the end of the study in responders, while non-responders
slept an average of 15 min less from baseline to post-
treatment 2. Comparison of the difference scores in actigra-
phy measures from baseline to post treatment 2 between
groups revealed that the mean change (improvement) scores
in TST were signiﬁcantly greater in the responders group
compared to non-responders (Wilcoxon¼2.21, p¼0.028).
For the measure of sleep efﬁciency (SE), baseline levels
were below the “normal” threshold of 85% [25]. SE showed
some improvement for the responders from baseline to post
treatment week 2 compared to non-responders (Table 2). At
baseline responders had about 10% less SE than non-
responders and they gained this 10% by the post treatment
2 data point. In contrast, non-responders gained less than 4%
improvement in SE. SE change scores tended to be greater in
the responders than non-responders (p¼0.07).
Sleep onset latency (SOL) tended to improve from baseline
to post treatment week 2 for the responders (42.1–17.75 min;
Table 3 – Mean and standard deviations of actigraphy
variables, averaged across each week for each study
period (baseline, treatment, post treatment 1, post treat-
ment 2). Repeated measures ANOVA results also shown.
N Mean Std. deviation
Baseline rest time (min) 18 544.46 55.83
Treatment week rest time (min) 17 542.26 84.11
Post 1 rest time (min) 15 520.37 59.47
Post 2 rest time (min) 13 516.38 71.73
(F2.33, 27,91¼2.23, p¼0.12; partial η2¼0.16)
Baseline sleep efﬁciency (%) 16 78.31 9.51
Treatment sleep efﬁciency (%) 16 79.96 7.94
Post 1 sleep efﬁciency (%) 14 82.66 6.26
Post 2 sleep efﬁciency (%) 11 84.15 3.33
(F2.54, 25.38¼0.90, p¼0.44; partial η2¼0.08)
Baseline WASO 17 75.86 50.00
Treatment WASO 17 73.56 33.56
Post 1 WASO 15 60.55 25.90
Post 2 WASO 13 70.21 42.70
(F2.19, 24.03¼0.47, p¼0.65; partial η2¼0.04)
Baseline TST (min) 16 442.64 56.59
Treatment TST (min) 17 430.63 66.10
Post 1 TST (min) 15 421.12 51.46
Post 2 TST (min) 13 416.30 55.20
(F1.98, 19.79¼1.10, p¼0.35; partial η2¼0.10)
Baseline SOL (min) 18 27.86 39.07
Treatment SOL (min) 17 21.40 18.02
Post 1 SOL (min) 15 23.72 28.43
Post 2 SOL (min) 13 21.07 21.06
(F2.18, 23.94¼0.74, p¼0.50; partial η2¼0.06)
Baseline # wake bouts 18 27.54 11.74
Treatment # wake bouts 17 29.47 9.44
Post 1 # wake bouts 15 27.70 8.91
Post 2 # wake bouts 13 28.60 10.37
(F1.81, 21.67¼0.52, p¼0.59; partial η2¼0.04)
Baseline SFI 17 43.42 28.55
Treatment SFI 17 44.70 22.42
Post 1 SFI 15 33.14 9.86
Post 2 SFI 13 36.56 16.69
(F2.41, 26.50¼1.75, p¼0.19; partial η2¼0.14)
WASO¼wake after sleep onset; TST¼total sleep time; SOL¼sleep
onset latency; SFI¼sleep fragmentation index.
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responders (Table 2). The difference scores for responders
compared to the non-responders was not signiﬁcant (p¼0.08).
As SOL 430 min is considered abnormal, this change indi-
cates that treatment improved the responder group mean
SOL from an abnormal to normal duration [25].
Means and standard deviations of the four day averages for
the actigraphy measures for the whole group and the repeated
measures ANOVA results are shown in Table 3. The analyses
revealed that sleep fragmentation index and time in bed showed
improvements (reduction in both parameters) across the study,
however these changes did not reach statistical signiﬁcance.
Sleep efﬁciency, sleep onset latency, WASO, total sleep time and
the number of wake bouts did not change across the study.
3.4. Subjective measures
Means and standard deviations of the subjective sleep,
fatigue and mood scales rated by patients who demonstratedthe required alteration of bacterial viable counts following
treatment (responders) and those who did not respond to
treatment are shown in Table 4. No signiﬁcant change in any
of the subjective measures was observed between baseline
and the two follow-up points for responders versus non-
responders.
Table 5 shows the scores of the CFS symptoms, subjective
sleep quality, Chalder Fatigue Scale and POMS questionnaire
scores for the whole group across the study. Average weekly
ratings of sleep quality improved signiﬁcantly across the
3 weeks. There was a signiﬁcant improvement in subjective
sleep quality from Day 7 to Day 22 (t(21)¼2.52, p¼0.020) and
from Day 15 to Day 22 (t(21)¼2.99, p¼0.007). There was no
signiﬁcant difference in CFS symptoms total ratings score
between baseline and after the end of the trial (t(18)¼1.12,
p¼0.280). Similarly, there were no difference in any POMS
subscales or Chalder Fatigue Scale scores between Day 7 and
Day 14 (immediately following antibiotic treatment), or
between Day 7 and Day 22 (end of the trial) (all p0s40.05).
3.5. Correlational analyses for mood
Although the sample size of responders was small (n¼7), a
signiﬁcant, and large, negative correlation between Strepto-
coccus viable count and POMS vigor subscale (ρ¼0.90,
p¼0.037) was found at post treatment 2, indicating improved
mood with a lower Streptococcus count. At this time point
there were strong positive correlations between Lactobacillus
percentage distribution and POMS total score (ρ¼0.83,
p¼0.042), and the confusion (ρ¼0.84, p¼0.036), anger
(ρ¼0.84, p¼0.036) and depression (ρ¼0.84, p¼0.036) POMS
subscales, and a negative correlation with POMS vigor sub-
scale (ρ¼0.83, p¼0.042). These indicate poorer mood with
higher Lactobacillus in the responders at the end of the trial.
Spearman's correlations across the whole group similarly
revealed that Lactobacillus viable counts at the end of the trial
(n¼21) were signiﬁcantly and positively correlated with POMS
total score (ρ¼0.70, p¼0.001), POMS confusion subscale
(ρ¼0.60, p¼0.005), POMS tension subscale (ρ¼0.47, p¼0.038),
POMS anger subscale (ρ¼0.67, p¼0.001) and POMS depression
subscale (ρ¼0.65, p¼0.002), indicating poorer mood with
higher Lactobacillus counts for all these scales. Similar results
were found between POMS scores and Lactobacillus percentage
distributions.4. Discussion
This open-label trial is the ﬁrst study to our knowledge to
report on changes in objective and subjective sleep and self-
reported symptoms in CFS patients after antibiotic treatment.
The primary ﬁnding from the study was evidence of an
improvement in several objective sleep parameters in parti-
cipants in whom the increased colonization of lactic acid
producing organisms was resolved after antibiotic treatment.
A second key ﬁnding of this study was that, across the whole
sample, there was an improvement in sleep quality ratings
over the course of the trial. This was not, however, associated
with objective improvements in sleep as measured by acti-
graphy. CFS symptoms and mood did not change signiﬁcantly
Table 4 –Mean and standard deviations (SD) of CFS symptoms, sleep, fatigue and mood across the study for the responders
and non-responders.
Day 7 Day 15 Day 22
Responders Mean
(SD)
Non responders
Mean (SD)
Responders Mean
(SD)
Non responders
Mean (SD)
Responders Mean
(SD)
Non responders
Mean (SD)
CFS symptoms 30.50 (13.98) 29.08 (13.28) – – 31.00 (14.42) 27.23 (13.36)
Sleep quality 4.63 (0.86) 4.77 (1.55) 4.82 (1.79) 4.88 (1.54) 5.63 (1.15) 5.33 (1.65)
Chandler Fatigue
Scale
13.01 (3.65) 14.90 (4.13) 15.78 (5.12) 13.89 (2.83) 14.64 (3.74) 14.08 (4.92)
POMS total score 44.86 (23.43) 33.36 (24.43) 50.30 (19.26) 34.43 (23.33) 40.00 (26.55) 34.86 (23.72)
POMS tension 6.29 (5.28) 6.79 (4.42) 9.29 (5.91) 5.71 (5.41) 9.00 (5.73) 6.29 (4.86)
POMS confusion 7.57 (4.86) 6.64 (4.34) 10.00 (4.08) 7.00 (4.24) 7.67 (4.72) 6.07 (3.83)
POMS fatigue 16.14 (3.98) 12.14 (5.49) 15.43 (5.09) 11.86 (5.46) 15.50 (6.16) 12.64 (5.94)
POMS vigor 4.00 (2.45) 5.29 (3.29) 3.57 (2.76) 4.36 (3.61) 6.00 (3.41) 3.93 (3.52)
POMS depression 11.57 (10.01) 7.64 (8.16) 13.29 (8.24) 7.50 (6.12) 8.33 (7.15) 6.64 (5.88)
POMS anger 29. (4.46) 5.86 (5.68) 6.00 (4.93) 6.34 (5.17) 5.50 (3.73) 6.93 (7.77)
CFS symptoms¼Chronic Fatigue Syndrome symptoms checklist; POMS¼Proﬁle of Mood States.
Note: for the POMS vigor subscale and sleep quality, higher scores indicate better symptoms. For all other scales, higher scores indicate worse
symptoms.
Table 5 – Mean and standard deviations of subjective CFS
symptoms, sleep, fatigue and mood across the study.
Day 7 (N¼22)
Mean (SD)
Day 15 (N¼22)
Mean (SD)
Day 22 (N¼21)
Mean (SD)
CFS symptoms
ratings
29.35 (12.80) – 28.15 (13.11)
Subjective sleep
qualityn
4.78 (1.32) 4.81 (1.56) 5.38 (1.46)
Chandler Fatigue
Scale
14.32 (3.90) 14.60 (3.66) 14.30 (4.37)
POMS total score 39.18 (25.38) 38.41 (23.24) 36.29 (23.40)
POMS tension 7.05 (4.91) 7.18 (5.71) 7.14 (5.01)
POMS confusion 7.14 (4.40) 8.09 (4.25) 6.47 (3.97)
POMS fatigue 13.55 (5.18) 13.05 (5.36) 13.57 (5.85)
POMS vigor 4.73 (3.03) 4.09 (3.22) 4.57 (3.44)
POMS depression 9.59 (8.07) 9.91 (7.43) 7.19 (5.99)
POMS anger 6.86 (5.68) 6.77 (5.46) 52. (6.57)
CFS symptoms¼Chronic Fatigue Syndrome symptoms checklist;
POMS¼Proﬁle of Mood States. Note: for the POMS vigor subscale
and sleep quality, higher scores indicate better symptoms. For all
other scales, higher scores indicate worse symptoms.
n Signiﬁcant difference between Day 7 and Day 15, and Day 7 and
Day 22 (po0.05).
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in a larger, placebo-controlled study is required.
It was anticipated in the current study that sleep (both
objectively and subjectively measured) would improve after
antibiotic treatment, as a result of a decreased colonization of
lactic acid producing organisms. When examining those
participants who showed a clinically signiﬁcant improvement
in faecal Streptococcus after treatment, some promising results
emerged, with a signiﬁcant increase of 44 min of total sleep
time. There is an important body of literature supporting the
link between immune dysfunction and alterations in sleep-wake behaviour in healthy populations [26,27]. One mechan-
ism that may mediate the sleep response to infection is an
increase the expression of cytokines (including TFN-α, nitric
oxide and prolactin) [28], many of which are intimately
involved with sleep regulation [29]. Some researchers have
suggested that it is the effect of cytokines on various organs,
such as the brain, which could be an important mechanism
in producing the symptoms of CFS [30], particularly in rela-
tion to sleep. Thus a potential mechanism for improvements
in sleep may a reduction in circulating proinﬂammatory
cytokines as a result of improved gut health.
Importantly, however, only a subset of 7 of the 21 parti-
cipants showed a clinically signiﬁcant reduction in both
Streptococcus count and percentage distribution after 6 days
of erythromycin treatment, and therefore this ﬁnding war-
rants further investigation. Four participants showed an
increase in streptococcal levels at the end of the trial. It is
possible that these patients were non-responsive to the
antibiotics, or may be a result of an inadequate dosage or
treatment duration of the antibiotic. In general, the principle
of microbial suppression of anti-microbial agents is depended
ﬁrstly on the achievable concentration of the anti-microbial
agent in relation to the organism susceptibility proﬁle, and
secondly on the level of interference substance present at the
site with the index organism(s). As the lumen of the bowel is
grossly mixed, masking and/or interfering the activities of the
antimicrobial agent will occur, resulting in a diminished anti-
microbial effect against the organism(s), effecting a partial
suppression of the index organism. The understanding of
antimicrobial activities in the large bowel is at its infancy.
This study highlights the importance in understanding the
intestinal ecology and its management with antibiotics.
Erythromycin, a macrolide, was selected as the antibiotic of
choice for the study. The antibiotic, once absorbed, is excreted
into the intestine via the bile, and attains a high concentration in
the colon [31]. The bacteriostatic activity of erythromycin against
lactic acid producing organisms Streptococcus, Lactobacillus and
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ities against Enterococcus. The serum achievable concentration for
erythromycin is typically not adequate nor high to provide a
bactericidal effect for Enterococcus-related infections. Pharmaco-
kinetically, however, erythromycin can provide a positive sup-
pressive effect against speciﬁc intestinal organisms in the large
bowel. With the minimum inhibitory concentration (MIC) of
erythromycin for the organism Enterococcus is generally between
25–50mg/L, an oral dose of 400mg b.d. should result a change in
the organism viable count, as shown in the study. Differential
responses to the erythromycin antibiotic treatment may be
explained by the dosage of the antibiotic, frequency of admin-
istration, duration of treatment and/or the antibiotic appropri-
ateness targeting multi-strains of organisms. Examining dif-
ferent doses of erythromycin will help to determine whether
some patients require higher levels of antibiotics before treat-
ment responses are observed. Treatment periods of 6 days of
antibiotics are typically used in these patients by the clinician
involved in this trial, however longer treatment periods may also
be required. Probiotic use may also be beneﬁcial in restoring gut
ﬂora as may be needed after antibiotic treatment [15]. This
combined therapy may be required to observe clinical improve-
ments in symptoms. Given the potential for events that are
known to exacerbate CFS symptoms occurring that were outside
of the researchers' control (e.g. stress, over-activity), changes in
symptoms may have made any changes resulting from anti-
biotics difﬁcult to detect. Assessing a larger sample of patients in
longitudinal studies would help to overcome this variability in
symptom expression. While erythromycin treatment reduced
Streptococcus levels in some patients, it also signiﬁcantly dimin-
ished levels of Lactobacillus and Biﬁdobacteria in these patients.
Alterations in Biﬁdobacteria, and anaerobes in general, have been
shown to amplify the domination of cytokines in the system in
patients with ulcerative colitis [32]. Treatments typically incor-
porate both antibiotic and probiotic treatments to balance and
restore microﬂora. Thus this single treatment alone may not
have been sufﬁcient to improve symptoms, as the system needs
a balance of microbiota for optimal health. Research examining
treatment outcomes of longer and more targeted therapeutic
protocols with different dosages of antibiotics is needed.
Study inclusion for the current trial required self-reported
unrefreshed or disturbed sleep. Although sleep disturbances are
a hallmark feature of CFS [1], only a proportion of the partici-
pants had poor sleep over the baseline week of the study, as
measured by actigraphy. There are a few possible explanations
for this. Firstly, symptoms often ﬂuctuate in these patients, and
while generally the participants in the study had poor sleep,
some participants may have had better sleep during the baseline
week. Secondly, while CFS patients often report the symptom of
unrefreshed sleep [1], this poorly understood sleep complaint [33]
may not be accurately measured by actigraphic variables. In fact,
although not presented in the results, we did not ﬁnd any
association between the objective actigraphy variables and
subjective sleep ratings at baseline, consistent with the well-
documented dissociation between objective and subjective sleep
measurements [34,35]. This raises the issue of how sleep is best
assessed in CFS patients (for further discussion see [1]).
Results from the correlation analysis for both responders and
the whole group revealed that higher Lactobacillus viable counts
were signiﬁcantly associated with poorer overall mood,including higher levels of confusion, depression and anger. In
responders, lower Streptococcus viable count at the end of the trial
was associated with better subjective sleep quality and vigor
ratings. These ﬁndings highlight that commensal intestinal
organisms, if disturbed, have the ability to inﬂuence emotional
responses and behavior [36]. While the Lactobacillus ﬁnding is not
in line with previous studies reporting a reduction in depressive
and anxiety symptoms after probiotic treatment in both healthy
[37] and CFS populations [15], the current ﬁndings do support the
D-lactate hypothesis. Possible explanations for the discrepancy
between this and previous studies may be differences in the
speciﬁc strain of Lactobacillus, which may have more protective
or pathogenic qualities [38], or an adverse interaction between
increased Lactobacillus levels and other organisms in the large
intestine. Most lactobacilli produce both L- and D- lactic acids. It
is possible that the association shown between Lactobacillus and
mood in our study may be inﬂuenced by interactions with other
microbes, for example the combination of high levels of Lacto-
bacillus and Streptococcus may be more detrimental to the host.
Further to this, Rao et al. (2009) showed that supplementation
with Lactobacillus also increased Biﬁdobacterium levels at post-
testing, and this was associated with decreased anxiety in CFS
patients. Thus, it is difﬁcult to determine the direct inﬂuence of a
speciﬁc microbe, given the complex and interactive nature of the
gut ecosystem.
The current pilot study was conducted as an open label trial,
without a placebo group. Instead, with the study design includ-
ing different phases (baseline, treatment and follow up), each
patient essentially became their own control. The beneﬁt of such
a design is that it reduces the between-group variability in
symptom severity that is commonly found between patients
with CFS. However, this design is limited by individual ﬂuctua-
tions in CFS patients' symptoms, as well as changes or differ-
ences in diet and exercise within and between participants,
which may independently alter the outcome measures. There is
also the possibility of placebo effects on our subjectivemeasures.
Interestingly, placebo effects in the CFS population are low with
psychological interventions, but can be higher with immune-
based interventions [39]. Thus, while placebo effects would also
be expected to be minimized by the use of objective sleep
monitoring, it could be argued that patient expectations of
improved sleep may in fact lead them to become more relaxed
during sleep which would be expressed through actigraphy. As
discussed above, actigraphic measures may not be able to detect
differences between non-restorative and restorative sleep, and
thus further studies using more sensitive measures of sleep
disturbance, such as polysomnography, are needed.5. Conclusion
Key contributions of this study are the suggestion that one week
of antibiotic treatment is insufﬁcient to effect important changes
in the gut ecosystem in most CFS participants, that reducing the
levels of gram-positive gut microbiota is associated with some
improvement in objective sleep parameters and self-reported
vigor in CFS patients, and that high levels of Lactobacilli may be
detrimental to mood. In sum, this pilot study provides prelimin-
ary evidence that changes to microbiota in a clinical population
(CFS) may alter sleep. However, changes to the antibiotic regime,
S l e e p S c i e n c e 8 ( 2 0 1 5 ) 1 2 4 – 1 3 3132adding a placebo control group, using a larger sample size and
measuring sleep polysomnographically are needed to clarify and
extend these ﬁndings.Conﬂict of interest
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